The list of risks above is not exhaustive.
The list of risks above is not exhaustive. Submitted our Annual Report on Form 20-F Securities and Exchange Commission Securities and Exchange Commission, and other documents with or furnished to the Securities and Exchange Commission filings are additional factors that may affect our businesses and financial performance. We expressly disclaim any obligation or undertaking any forward-looking publicly or revise any forward-looking statements with respect to change in our expectations or any change events, conditions or circumstances on which any such statements are based.
And internationally.. About Evotec AG. Evotec is a leader in the discovery and development of novel small molecule drugs has its own discovery programs and through research collaborations, generating the highest quality research results to its partners in the pharmaceutical and biotech industries in the. Proprietary projects , Evotec has on the development of new therapies for diseases of the central nervous system, Evotec has three programs in clinical development. EVT 201, a partial positive allosteric modulator of the GABAA receptor complex for the treatment of insomnia, EVT 101 a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and / or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.The Phase IIa trial is a randomized, double-blind, placebo-controlled design, where Alzheimer patients get three month either one of three oral doses PBT2 , or placebo. Besides assessing the safety and tolerance the degree is the capacity from PBT2 multiple cerebrospinal fluid and the blood biomarkers of Alzheimer disease impact during the treatment period. Proof-of belong measures to the CSF A – beta Time and rope levels and neurocognitive and behavioral changes.
The Conference CalPrana causes a teleconference to discuss the the stage I clinical trials data and her plans for the stage IIa trial Monday 15 at 5:00 Eastern Time Clock (07.00 Melbourne period Clock on Tuesday.